Tandem Diabetes director awarded 10,220 RSUs

Tandem Diabetes Care director Myoungil Cha increased equity exposure through stock-based compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tandem Diabetes Care director Myoungil Cha increased equity exposure through stock-based compensation. On May 21, 2026, 8,759 previously granted restricted stock units vested and converted into the same number of common shares under the company’s 2023 Long-Term Incentive Plan. On May 20, 2026, Cha also received a new award of 10,220 restricted stock units that will vest on the one-year anniversary of that grant, subject to plan terms. Following these transactions, Cha directly owns 22,458 shares of common stock.

Insider Trade Summary

8,759 shares exercised/converted

Exercise 3 txns

Insider Cha Myoungil

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	8,759	$0.00	$0.00
Exercise	Common Stock	8,759	$0.00	$0.00
Grant/Award	Restricted Stock Unit	10,220	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 10,220 contracts (Direct); Common Stock — 22,458 shares (Direct)

Footnotes (3)

F1. Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F2. Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.
F3. On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.

Key Figures

RSUs vested and converted: 8,759 units New RSU grant: 10,220 units Shares held after transactions: 22,458 shares +2 more

5 metrics

RSUs vested and converted 8,759 units Restricted stock units converted into common stock on May 21, 2026

New RSU grant 10,220 units Restricted stock units granted on May 20, 2026

Shares held after transactions 22,458 shares Common stock directly owned following reported Form 4 transactions

Transaction code M events 2 transactions Exercises/conversions of derivative securities reported in this Form 4

Transaction code A events 1 transaction Grant or award of restricted stock units on May 20, 2026

Key Terms

Restricted Stock Unit, 2023 Long-Term Incentive Plan, contingent right, Exercise or conversion of derivative security

4 terms

Restricted Stock Unit financial

"security_title": "Restricted Stock Unit""

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2023 Long-Term Incentive Plan financial

"in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan"

contingent right financial

"Each restricted stock units (RSU) represents a contingent right to receive either one share"

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Tandem Diabetes Care (TNDM) report for Myoungil Cha?

Tandem Diabetes Care reported that director Myoungil Cha had 8,759 restricted stock units vest and convert into common stock and received a new grant of 10,220 restricted stock units, all under the company’s 2023 Long-Term Incentive Plan.

How many Tandem Diabetes Care (TNDM) shares does Myoungil Cha hold after these Form 4 transactions?

After the reported transactions, Myoungil Cha directly holds 22,458 shares of Tandem Diabetes Care common stock. This reflects the conversion of 8,759 restricted stock units into shares while retaining a new restricted stock unit grant for potential future settlement.

What restricted stock unit grants are disclosed for Tandem Diabetes Care (TNDM) director Myoungil Cha?

The filing shows two restricted stock unit grants: 8,759 units granted on May 21, 2025, which later fully vested and converted into common stock, and 10,220 units granted on May 20, 2026 that will vest on the one-year anniversary of that grant, subject to plan terms.

When will the new restricted stock units for Tandem Diabetes Care (TNDM) director vest?

The 10,220 restricted stock units granted to director Myoungil Cha on May 20, 2026 will vest on the one-year anniversary of that grant, assuming continued satisfaction of the conditions in the company’s 2023 Long-Term Incentive Plan and related agreements.

Did the Tandem Diabetes Care (TNDM) Form 4 show any stock sales by Myoungil Cha?

The Form 4 does not report any stock sales by Myoungil Cha. It only shows derivative exercises and awards: vesting and conversion of 8,759 restricted stock units into common stock and a new grant of 10,220 restricted stock units under the 2023 Long-Term Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/22/2026 - 04:04 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cha Myoungil

(Last)

(First)

(Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		M		8,759	A	$0	22,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	05/20/2026		A		10,220		⁽²⁾	⁽²⁾	Common Stock	10,220	$0	10,220	D
Restricted Stock Unit	⁽¹⁾	05/21/2026		M			8,759	⁽³⁾	⁽³⁾	Common Stock	8,759	$0	0	D

Explanation of Responses:

1. Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

2. Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.

3. On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.

Remarks:

Ex. 24: Power of Attorney

	/s/ Jerilyn Laskie, Attorney-in-Fact for Myoungil Cha	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR